Skip to main content

Table 5 Comparison of the percentages of γδ T cell subsets in IFN-β-treated MS patients stratified to the NEDA or EDA groups

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

 

MS w/IFN-β

HCs (n = 44)

p value (K-W test)

padj value

NEDA (n = 8)

EDA (n = 13)

NEDA vs. HCs

EDA vs. HCs

NEDA vs. EDA

Vδ1+

39.5 (21.1–55.9)

17.4 (11.6–38.5)

18.4 (11.6–34.2)

NS

 Vδ1+Vγ9+

3.01 (1.32–10.7)

2.99 (1.60–3.94)

2.15 (1.12–4.71)

NS

 Vδ1+Vγ9

36.4 (17.5–51.9)

15.2 (9.18–31.9)

15.5 (8.47–31.5)

NS

Vδ2+

14.2 (3.17–25.2)

24.7 (6.33–42.9)

54.9 (31.7–65.9)

< 0.001

< 0.001

0.006

NS

 Vδ2+Vγ9+

14.1 (2.76–25.0)

24.3 (6.09–42.8)

54.3 (31.1–65.7)

< 0.001

< 0.001

0.005

NS

 Vδ2+Vγ9

0.12 (0.00–0.26)

0.18 (0.06–0.84)

0.08 (0.03–0.29)

NS

Vδ1Vδ2

32.3 (20.0–61.8)

36.1 (28.4–54.0)

22.8 (17.1–30.3)

< 0.001

0.033

< 0.001

NS

 Vδ1Vδ2Vγ9+

1.68 (0.30–2.83)

1.01 (0.26–2.23)

2.42 (1.25–3.83)

0.025

NS (0.061)

0.022

NS

 Vδ1Vδ2Vγ9

28.2 (17.1–60.7)

35.1 (27.5–51.0)

18.1 (10.7–26.4)

< 0.001

0.011

< 0.001

NS

  1. Values are the median (IQR). Percentages of each population in total γδ T cells are shown
  2. p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
  3. EDA evidence of disease activity, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NEDA no-evidence of disease activity, NS not significant, w/ with